The Sad Truth: This Biotech Investing Strategy Almost Always Works [The Motley Fool]
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: The Motley Fool
We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication. Treating disease is a big-money business for pharmaceutical and biotech companies. What was a $1.1 trillion market in 2016 is expected to lead to $1.5 trillion in global drug sales by 2021. With a growing global population and no shortage of diseases left to be treated, investors would think that putting their money to work in drug developers would be a smart idea. But therein lies the rub: Not all clinical trials prove successful. In fact, a vast majority of hopeful drugs will fall flat on their face at some point during the discovery, laboratory, preclinical, or clinical-testing process. According to Medscape, just one out of every 5,000 to 10,000 drug hopefuls tested in preclinical trials will get the green light from the Food and Drug Administration and find their way to pharmacy shelves. Image source: Getty Ima
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $400.00 price target on the stock.MarketBeat
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safety [Yahoo! Finance]Yahoo! Finance
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safetyPR Newswire
- Axon Enterprise (AXON) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 4/19/24 - Form POSASR
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEFA14A
- AXON's page on the SEC website